Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. News
  7. Summary
    2500   CNE100003PJ8

VENUS MEDTECH (HANGZHOU) INC.

(2500)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Venus Medtech Hangzhou Inc. Reports Earnings Results for the Half Year Ended June 30, 2021

08/31/2021 | 09:21am EST

Venus Medtech Hangzhou Inc. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 239.269 million compared to CNY 102.049 million a year ago. Net loss was CNY 113.063 million compared to CNY 43.524 million a year ago. Basic loss per share from continuing operations was CNY 0.26 compared to CNY 0.11 a year ago.


ę S&P Capital IQ 2021
All news about VENUS MEDTECH (HANGZHOU) INC.
2021Venus Medtech Completes First-in-Human Study of Heart Valve Product; Shares Jump 7%
MT
2021Venus Medtech Inc. Announces Completion of Global First Clinical Application of Venus-P..
CI
2021Venus Medtech Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Suc..
CI
2021Venus Medtech Inc. commences an Equity Buyback Plan for 43,170,744 shares, representing..
CI
2021Venus Medtech Taking Full Ownership of Israeli Medical Device Maker Mitraltech; Shares ..
MT
2021Venus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitr..
PR
2021Venus Medtech in Talks With Private Healthcare Provider for Specialist Center Project; ..
MT
2021Venus Medtech Inc. Enters into Strategic Cooperation Framework Agreement with United Fa..
CI
2021VENUS MEDTECH HANGZHOU : Chinese Regulators Accept Venus Medtech's Registration Applicatio..
MT
2021Venus Medtech Announces Registration Application of TriGUARD3TM Accepted by NMPA
CI
More news
Financials
Sales 2021 505 M 79,5 M 79,5 M
Net income 2021 -138 M -21,7 M -21,7 M
Net cash 2021 2 478 M 391 M 391 M
P/E ratio 2021 -87,7x
Yield 2021 -
Capitalization 12 020 M 1 543 M 1 894 M
EV / Sales 2021 18,9x
EV / Sales 2022 10,6x
Nbr of Employees 675
Free-Float -
Chart VENUS MEDTECH (HANGZHOU) INC.
Duration : Period :
Venus Medtech (Hangzhou) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS MEDTECH (HANGZHOU) INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 27,45 CNY
Average target price 46,24 CNY
Spread / Average Target 68,4%
EPS Revisions
Managers and Directors
Zhen Jun Zi Executive Director & General Manager
Haiyue Ma Chief Financial Officer & Joint Secretary
Min Zeng Chairman
Yan Xiao Chairman-Supervisory Board
Hou-Sen Lim Chief Technology & Operating Officer
Sector and Competitors